NightHawk be­comes pure-play CD­MO; Lon­za to make liv­er can­cer drug; BioN­Tech gears up to open first site in Africa

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

NightHawk is to be­come a pure-play CD­MO by end­ing its R&D ac­tiv­i­ties and di­vest­ing its biode­fense sub­sidiary Elusys, ac­cord­ing to a Tues­day an­nounce­ment. NightHawk will now on­ly fo­cus on its man­u­fac­tur­ing sub­sidiary Scor­pius Bio­Man­u­fac­tur­ing, which has gen­er­at­ed over $20 mil­lion in rev­enue dur­ing its first year of op­er­a­tions. Elusys will be tak­en over by a pri­vate com­pa­ny owned by NightHawk CEO Jeff Wolf.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER